circSLC25A13 acts as a ceRNA to regulate AML progression via miR-616-3p/ADCY2 axis

Circular RNAs (circRNAs), a type of endogenous noncoding RNA (ncRNA), exert vital roles in leukemia progression and are promising prognostic factors. Here, we report a novel circRNA, circSLC25A13 (hsa_circ_0081188), which was increased in acute myeloid leukemia (AML) patients with poor overall survival (OS) comparing to patients with good prognosis. Knockdown of circSLC25A13 in AML cells inhibited proliferation and increased cell apoptosis in vitro and in vivo. Enhanced circSLC25A13 expression promoted the survival of AML cells. Mechanistically, circSLC25A13 played as a microRNA sponge of miR-616-3p, which inhibited the expression of adenylate cyclase 2 (ADCY2). Downregulation of miR-616-3p and overexpression of ADCY2 partially rescued circSLC25A13 deficient induced cell growth arrest. In summary, through competitive absorption of miR-616-3p and thereby upregulating ADCY2 expression, circSLC25A13 promoted AML progression. Moreover, circSLC25A13 may represent a potential novel biomarker for the prognosis of AML and offer a potential therapeutic target for AML treatment.

Automated summary

A novel circRNA, circSLC25A13, was found to be increased in acute myeloid leukemia (AML) patients with poor overall survival (OS). Knockdown of circSLC25A13 inhibited AML cell proliferation and increased apoptosis in vitro and in vivo. Mechanistically, circSLC25A13 acted as a miR-616-3p sponge, promoting AML progression by upregulating ADCY2 expression. Therefore, circSLC25A13 may serve as a potential biomarker for AML prognosis and a therapeutic target for AML treatment.